Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
Abstract Introduction To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3 DISCOVER-2 clinical trial. Methods Adult patients w...
Main Authors: | Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P. Kollmeier, Natalie J. Shiff, Chenglong Han, May Shawi, William Tillett, Philip J. Mease |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2024-02-01
|
Series: | Rheumatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40744-024-00642-9 |
Similar Items
-
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
by: Philip J. Mease, et al.
Published: (2023-10-01) -
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
by: Laura C. Coates, et al.
Published: (2024-02-01) -
Guselkumab-induced vitiligo in a patient with psoriatic arthritis
by: Fabrizio Martora, MD, et al.
Published: (2023-11-01) -
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2023-08-01) -
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
by: Ana-Maria Orbai, et al.
Published: (2023-09-01)